Lexotanil 3mg indications
Lexotanil 3mg is an intermediate-acting tranquiliser, prescribed for the treatment of moderate to severe anxiety and panic disorders and for the short-term treatment of insomnia. Unlike the benzodiazepine alprazolam it does not possess any antidepressant qualities.
In low doses it diminishes anxiety and tension. In higher doses the sedative and muscle-relaxant properties appear.
Lexotanil 3mg description
Lexotanil 3mg is 7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one.
Lexotanil 3mg dosage
Average Dosing for Outpatient Therapy: 1.5-3 mg up to 3 times daily.
Severe Cases, Especially in Hospital: 6-12 mg 2 or 3 times daily.
These amounts are general recommendations, and dosage should be individually determined. Treatment of outpatients should begin with low doses, gradually increasing to the optimum level. The duration of treatment should be as short as possible. The patient should be re-assessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free. The overall treatment generally should not be >8-12 weeks, including a tapering-off process. In certain cases, extension beyond the maximum treatment period may be necessary, if so, it should not take place without re-evaluation of the patient's status with special expertise.
Special Dosage Instructions: Lexotanil 3mg is usually not indicated in children, but if the physician feels Lexotanil 3mg treatment is appropriate, then the dose should be adjusted to their low body weight (about 0.1–0.3 mg/kg body weight).
Elderly patients and those with impaired hepatic function require lower doses because of individual variations in sensitivity and pharmacokinetics.
Lexotanil 3mg interactions
Pharmacokinetic Drug-Drug Interaction (DDI): There is a possibility that compounds, which inhibit certain hepatic enzymes, may influence the activity of those benzodiazepines that are metabolised by these enzymes. Co-administration of cimetidine may prolong the elimination t½ of Lexotanil 3mg through a substantially reduced clearance (with cimetidine, reduction by 50%). Combined administration with fluvoxamine, an inhibitor of CYP1A2, results in significantly increased Lexotanil 3mg exposure (AUC, 2.4-fold) and elimination t½ (1.9-fold).
Lexotanil 3mg does not induce oxidative hepatic enzymes at therapeutic doses.
Pharmacodynamic Drug-Drug Interaction (DDI): Enhanced effects on sedation, respiration and hemodynamics may occur when Lexotanil 3mg is co-administered with any centrally-acting depressants including alcohol.
Alcohol should be avoided in patients receiving Lexotanil 3mg.
For warning of other CNS depressants, including alcohol, see Overdosage.
In the case of narcotic analgesics, enhancement of euphoria may also occur, leading to an increase in psychic drug dependence.
Lexotanil 3mg side effects
Post-Marketing: Lexotanil 3mg is well tolerated in therapeutic doses. The following adverse reactions may occur: Psychiatric Disorders: Confusional state, emotional disorder. These phenomena occur predominantly at the start of therapy and usually disappear with repeated administration. Libido disorders have been reported occasionally.
Depression: Preexisting depression may be unmasked during benzodiazepine use.
Paradoxical Reactions eg, restlessness, agitation, irritability, aggression, delusion, anger, nightmares, hallucinations, psychosis, inappropriate behaviour and other adverse behavioural effects are known to occur with benzodiazepines or benzodiazepine-like agents. Should this occur, the use of Lexotanil 3mg should be discontinued. They are more likely to occur in children and elderly patients than in other patients.
Dependence: Chronic use (even at therapeutic doses) may lead to the development of physical and psychic drug dependence: Discontinuation of therapy may result in withdrawal or rebound phenomena.
Abuse of benzodiazepines has been reported.
Nervous System Disorder: Drowsiness, headache, dizziness, decreased alertness, ataxia. These phenomena occur predominantly at the start of therapy and usually disappear with repeated administration.
Anterograde amnesia may occur using therapeutic dosages, the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behaviour.
Eye Disorders: Diplopia, this phenomenon occurs predominantly at the start of therapy and usually disappears with repeated administration.
Gastrointestinal Disorders: Gastrointestinal disorders have been reported occasionally.
Skin and Subcutaneous Tissue Disorders: Skin reactions have been reported occasionally.
Musculoskeletal and Connective Tissue Disorders: Muscle weakness, this phenomenon occurs predominantly at the start of therapy and usually disappears with repeated administration.
General Disorders and Administration Site Conditions: Fatigue, this phenomenon occurs predominantly at the start of therapy and usually disappears with repeated administration.
Injury, Poisoning and Procedural Complications: There have been reports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives (including alcoholic beverages) and in the elderly.
Respiratory Disorders: Respiratory depression.
Cardiac Disorders: Cardiac failure including cardiac arrest.
Lexotanil 3mg contraindications
contraindicated in patients with:
• known hypersensivity to benzodiazepines
• severe respiratory insufficiency, including chronic obstructive airways disease with incipient
respiratory failure
• severe hepatic insufficiency as it may cause encephalopathy
• sleep apnoea syndrome
• myasthenia gravis.
may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression
Active ingredient matches for Lexotanil 3mg:
Bromazepam in Oman, Switzerland.
List of Lexotanil 3mg substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Lexotanil Roche 3 mg (Austria) | |
| Lexzepam (Indonesia) | |
| Lexzepam 3 (Indonesia) | |
| Lexzepam 3 3 mg x 5 x 10's (Mersifarma TM) | $ 18.54 |
| Libronil (Greece) | |
| Libronil 5 mg x 100's (Hexpharm) | $ 1.93 |
| Libronil-R (Greece) | |
| Lorival (Pakistan) | |
| Lucita 12 (Uruguay) | |
| Lucita 6 (Uruguay) | |
| Lucitan | |
| Mitransil 12 (Paraguay) | |
| Mitransil 3 (Paraguay) | |
| Mitransil 6 (Paraguay) | |
| Neo OPT (Germany) | |
| Nerfanil (Paraguay) | |
| Nervan (Venezuela) | |
| Neurilan (Brazil) | |
| Neurozepam (Argentina) | |
| Nightus (Bangladesh) | |
| Normoc (Germany) | |
| Norry (Bangladesh) | |
| Notens (Bangladesh) | |
| Notens 0.25 mg Tablet (Cyper Pharma) | $ 0.01 |
| Notorium (Greece, Malta) | |
| Novazepam | |
| Novepam (Oman) | |
| Novepam 1.5mg (Oman) | |
| Novepam 3mg (Oman) | |
| Novepam-1.5 | |
| Novepam-3 | |
| Novepam-6 | |
| Novo-Bromazepam | |
| Tablet; Oral; Bromazepam 3 mg | |
| Tablet; Oral; Bromazepam 6 mg | |
| Nu-Bromazepam | |
| Tablet; Oral; Bromazepam 1.5 mg | |
| Tablet; Oral; Bromazepam 3 mg | |
| Tablet; Oral; Bromazepam 6 mg | |
| Nulastres (Argentina) | |
| Octanyl (Argentina, Colombia, Costa Rica, Dominican Republic, El Salvador, Honduras, Panama) | |
| Octanyl 12mg (Uruguay) | |
| Octanyl 6mg (Uruguay) | |
| Otedram (Mexico) | |
| Tablet; Oral; Bromazepam 3 mg | |
| Tablet; Oral; Bromazepam 6 mg | |
| Pascalium (Greece) | |
| Pascaloi | |
See 457 substitutes for Lexotanil 3mg | |
References
- PubChem. "bromazepam". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "bromazepam". http://www.drugbank.ca/drugs/DB01558 (accessed September 17, 2018).
- DTP/NCI. "bromazepam: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lexotanil 3mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lexotanil 3mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
2 consumers reported useful
Was the Lexotanil 3mg drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 2 | 100.0% | |
Consumer reported price estimates
No survey data has been collected yet3 consumers reported time for results
To what extent do I have to use Lexotanil 3mg before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 month and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Lexotanil 3mg. To get the time effectiveness of using Lexotanil 3mg drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 month | 1 | 33.3% | |
| 2 days | 1 | 33.3% | |
| 1 day | 1 | 33.3% | |
27 consumers reported age
| Users | % | ||
|---|---|---|---|
| 16-29 | 22 | 81.5% | |
| 30-45 | 3 | 11.1% | |
| 46-60 | 1 | 3.7% | |
| > 60 | 1 | 3.7% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
